%0 Journal Article
%T Mood Predicts Response to Placebo CPAP
%A Carl J. Stepnowsky
%A Wei-Chung Mao
%A Wayne A. Bardwell
%A Jos¨¦ S. Loredo
%A Joel E. Dimsdale
%J Sleep Disorders
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/404196
%X Study Objectives. Continuous positive airway pressure (CPAP) therapy is efficacious for treating obstructive sleep apnea (OSA), but recent studies with placebo CPAP (CPAP administered at subtherapeutic pressure) have revealed nonspecific (or placebo) responses to CPAP treatment. This study examined baseline psychological factors associated with beneficial effects from placebo CPAP treatment. Participants. Twenty-five participants were studied with polysomnography at baseline and after treatment with placebo CPAP. Design. Participants were randomized to either CPAP treatment or placebo CPAP. Baseline mood was assessed with the Profile of Mood States (POMS). Total mood disturbance (POMS-Total) was obtained by summing the six POMS subscale scores, with Vigor weighted negatively. The dependent variable was changed in apnea-hypopnea index (¦¤AHI), calculated by subtracting pre- from post-CPAP AHI. Negative values implied improvement. Hierarchical regression analysis was performed, with pre-CPAP AHI added as a covariate to control for baseline OSA severity. Results. Baseline emotional distress predicted the drop in AHI in response to placebo CPAP. Highly distressed patients showed greater placebo response, with a 34% drop (i.e., improvement) in AHI. Conclusion. These findings underscore the importance of placebo-controlled studies of CPAP treatment. Whereas such trials are routinely included in drug trials, this paper argues for their importance even in mechanical-oriented sleep interventions. 1. Introduction Placebo responses remain one of the great mysteries of medicine. While a clinical benefit of treatment (any treatment) is always a ˇ°plusˇ± for the patient, such placebo responses can complicate clinical trials. This paper examines some placebo response characteristics in patients being treated with continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA). OSA is a potentially devastating illness that involves sleep fragmentation and associated hypoxia, affecting up to 9% of middle-aged adults and higher percentages in the elderly [1¨C3]. The pathological consequences of upper airway obstruction during sleep may lead to cardiovascular complications, marked psychological distress, and impairment in daytime performance and cognitive functioning [4¨C9]. The most commonly used treatment is nasal CPAP [10, 11]. CPAP has been efficacious in improving many outcome measurements, especially in patients with severe OSA [12¨C15]. However, some researchers have reported inconsistencies in improvement, for example, a nonspecific (or placebo) effect of
%U http://www.hindawi.com/journals/sd/2012/404196/